25 June 2019 - - US-based emerging diagnostic company Veravas, Inc has appointed Joshua Soldo as the chief scientific officer and Carmen Wiley, Ph.D., as chief clinical officer, the company said.
Soldo and Dr. Wiley have made significant contributions towards the development of Veravas technology and as part of the executive team, they will support the advancement and commercialisation of the company's breakthrough sample prep products and novel diagnostics tests.
Soldo brings more than 20 years of experience in the diagnostics, life science and healthcare markets.
He is a subject matter expert in assay development and solid phase chemistry with multiple patents and publications.
Previously, he had a role in medical and scientific affairs, cardiac at Roche Diagnostics, where he developed and maintained relationships with the medical and scientific community and collaborated with investigators, clinicians, and institutions.
In this role, he specialised in comprehensive knowledge in cardiac care and cardiac biomarkers, and applied a broad knowledge of principles, practices, and procedures in the field of cardiology.
Prior to this, Soldo was vice president, scientific affairs at Anteo Diagnostics Ltd., where he accelerated the expansion and market penetration of the company's patented Mix and Go product into North America and Europe.
Additional roles include corporate director, scientific affairs at DiaSorin and senior development scientist, research and development at Beckman Coulter.
Soldo holds a bachelor's degree in biochemistry from the University of Minnesota where he graduated with honors.
Dr. Wiley is a highly-recognised clinical leader in chemistry and laboratory medicine who brings more than 18 years of experience in clinical chemistry and laboratory medicine.
She is currently the president of American Association for Clinical Chemistry.
Prior to Veravas, she was a regional manager of scientific affairs at Roche Diagnostics. In this role, she supported scientific information exchange in the area of cardiac biomarkers and was responsible for leading relationship development with the medical and scientific communities.
Prior to this, Wiley was the scientific director at Pathology Associates Medical Laboratories where she had medical and scientific oversight responsibilities for all laboratory testing and research and development.
Other roles include co-director of chemistry, immunology, and point of care at Providence Health and Services, Sacred Heart Hospital, and head of clinical chemistry in the division of laboratory medicine and pathology at the Marshfield Clinic.
Dr. Wiley earned her bachelor's degree in chemistry from the University of Minnesota, where she graduated with honors, and her master and doctoral degrees in organic chemistry from University of Washington, and was a COMACC Accredited Fellow at the Mayo School of Medicine. She is board certified by American board of Clinical Chemistry and a Fellow of the Academy of AACC.
To date, the company has secured more than USD 2m in seed funding and is preparing to launch its first suite of products.
Veravas is transforming laboratory medicine with technology that delivers superior test results, providing confidence to clinicians and patients that diagnoses are accurate.
The company is driving the commercialisation of proprietary sample preparation products and new diagnostic tests. Veravas' nano magnetic particles can identify, remove, and measure select substances from patient samples to reduce the effects of complex interferences and detect low-abundance biomarkers. 
Led by a passionate and dedicated team, Veravas is devoted to improving patient lives by minimising the harmful effects of unnecessary treatments and deaths associated with poor quality diagnostic results.
Because every patient deserves the correct result, every time.